GNI Group (F351 Program) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
GNI Group (F351 Program) General Information
Description
Portfolio of advanced liver fibrosis drug development in Tokyo, Japan.
Contact Information
Corporate Office
- Nihonbashi-Honcho YS Building 3rd Floor
- 2-2-2 Nihonbashi-Honcho, Chuo-ku
- Tokyo, 103-0023
- Japan
Corporate Office
- Nihonbashi-Honcho YS Building 3rd Floor
- 2-2-2 Nihonbashi-Honcho, Chuo-ku
- Tokyo, 103-0023
- Japan
GNI Group (F351 Program) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GNI Group (F351 Program) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
GNI Group (F351 Program) FAQs
-
Where is GNI Group (F351 Program) headquartered?
GNI Group (F351 Program) is headquartered in Tokyo, Japan.
-
What industry is GNI Group (F351 Program) in?
GNI Group (F351 Program)’s primary industry is Buildings and Property.
-
Is GNI Group (F351 Program) a private or public company?
GNI Group (F351 Program) is a Private company.
-
What is the current valuation of GNI Group (F351 Program)?
The current valuation of GNI Group (F351 Program) is .
-
What is GNI Group (F351 Program)’s current revenue?
The current revenue for GNI Group (F351 Program) is .
-
Who are GNI Group (F351 Program)’s investors?
GNI Group has invested in GNI Group (F351 Program).
-
When was GNI Group (F351 Program) acquired?
GNI Group (F351 Program) was acquired on 15-Feb-2023.
-
Who acquired GNI Group (F351 Program)?
GNI Group (F351 Program) was acquired by Gyre Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process